Erythema annulare centrifugum-type eruption in a patient undergoing cancer vaccine immunotherapy
| dc.contributor.author | Tadros, Joseph | |
| dc.contributor.author | Rahnama-Moghadam, Sahand | |
| dc.contributor.department | Dermatology, School of Medicine | en_US |
| dc.date.accessioned | 2019-06-18T18:31:29Z | |
| dc.date.available | 2019-06-18T18:31:29Z | |
| dc.date.issued | 2018-10-15 | |
| dc.description.abstract | Sipuleucel-T is a cellular immunotherapy approved for the treatment of metastatic castration-resistant prostate cancer. We report a patient developing an immune related adverse effect from sipuleucel-T drug-induced erythema annulare centrifugum-like eruption. A brief review of the mechanism and implications of this eruption are also included. | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.identifier.citation | Tadros, J., & Rahnama-Moghadam, S. (2018). Erythema annulare centrifugum-type eruption in a patient undergoing cancer vaccine immunotherapy. Dermatology Online Journal, 24(10). | en_US |
| dc.identifier.issn | 1087-2108 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/19629 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Dermatology Online Journal | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/us | * |
| dc.source | Publisher | en_US |
| dc.subject | immunotherapy | en_US |
| dc.subject | immune related adverse events | en_US |
| dc.subject | erythema annulare centrifugum | en_US |
| dc.subject | Sipuleucel-T | en_US |
| dc.title | Erythema annulare centrifugum-type eruption in a patient undergoing cancer vaccine immunotherapy | en_US |
| dc.type | Article | en_US |